SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Video of clashes over purported conscription orders misrepresented as anti-war protest in Israel - 2The Electric Bicycle Americans Can Confide in 2024
- 3Kuwait is softening stance on Israel, dissident tells ‘Post’ after viral UN speech
- 4A Manual for Pick Dependable Vehicle Rental Administrations For 2024
- 5Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
- Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know
- Heart disease risk greater for women with a common condition they may not be aware they have
- Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period
- Remain Cool and Solid: Top Summer Food sources for 2024
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- Must-See Attractions in Washington, D.C.
- At 72, Kathie Lee Gifford says aging isn’t what she expected. 'The golden years? It’s a lie.’
- Von der Leyen: Paris meeting sends signal of unity for Ukraine
